Am J Transplant, Volume 21, Suppl 3 Archives - Page 118 of 139 - ATC Abstracts

2021 American Transplant Congress
A Novel Liver Assist Device as a Bridge to Liver Transplantation in Acute on Chronic Liver Failure Patients with Multi-Organ Failure
S. Ahmad¹, I. W. Liou¹, J. Reyes², R. Bakthavatsalam³, N. C. Smith⁴, R. L. Carithers¹, C. Martin¹, D. Gao⁵
¹Medicine, University of Washington, Seattle, WA, ²Surgery, University of Washington, SEATTLE, WA, ³Surgery, University of Washington, Seattle, WA, ⁴Nursing, University of Washington, Seattle, WA, ⁵Engineering, University of Washington, Seattle, WA
*Purpose: Acute on chronic liver failure (AOCLF) occurs in nearly 25% of patients with acutely decompensated cirrhosis, with many developing multi-organ failure requiring ventilatory, vasopressor…
2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Matas⁸, A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Childrens Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO, ⁸U Minnesota, Minneapolis, MN
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…
2021 American Transplant Congress
The Effect of Daratumumab (Dara, Humanized Anti-CD38 Monoclonal Antibody) on Immune Cells In Vitro and in a HLA-Sensitized Kidney Transplant Patient (HS KTx Pt) Desensitized (DES) with Dara
S. Ge¹, M. Chu¹, A. De Guzman¹, E. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR), primarily mediated by B cells, plasma cells (PC) and antibodies (Ab), is an obstacle for successful transplantation in HS KTx Pts.…
2021 American Transplant Congress
The Impact of Donor and Recipient Age Differenceon Long Term Prognosis in Young Liver Transplant Recipients
A. Pita, A. Moro, J. C. McVey, D. J. Firl, M. Fujiki, T. Diago, C. Quintini, F. Aucejo, C. D. Kwon, K. V. Menon, K. Hashimoto, B. Eghtesad, C. Miller, K. Sasaki
The Cleveland Clinic, Cleveland, OH
*Purpose: Although the importance of donor and recipient age in liver transplant (LT) are well-studied, the prognostic influences of donor and recipient age differences are…
2021 American Transplant Congress
Impact of Covid-19 in Transplant Care: Attitudes, Feeling and Behaviors of Liver, and Kidney Pre and Post Transplant Patients
J. Ramos-Ayes
Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: The SARS-CoV-2(COVID-19) pandemic poses unique challenges for transplant patients, which may impact their attitudes, emotions and behaviors associated with transplant care. This study surveys…
2021 American Transplant Congress
Impact of Extended Living Donor Criteria on Donor Safety in Living Donor Liver Transplantation
J. KIM
Department of Surgery, Catholic University of Daegu College of Medicine, Daegu, Korea, Republic of
*Purpose: Donor safety is major concern during living donor liver transplantation (LDLT) and most transplant centers accept strict selection criteria although some centers have been…
2021 American Transplant Congress
The Learning Curve Associated with De Novo Tacrolimus XR Use in a Racially Diverse Kidney Transplant Population
F. Bartlett, T. Carcella, N. Patel, V. Rohan, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Tacrolimus XR (LCP-Tac) was approved for de novo dosing in kidney transplant recipients in 2018. In 2020, our center was challenged with a nationwide…
2021 American Transplant Congress
MDR-101-MLK-MERCURY Kidney Transplant Tolerance Study Update
D. Kaufman¹, S. Akkina², M. Stegall³, J. Piper⁴, A. O. Gaber⁵, E. Marin⁶, S. Busque⁷, D. Alonso⁸, M. De Vera⁹, A. Shah¹⁰, A. Patel¹¹, K. Chavin¹², M. Laftavi¹³, S. Collette¹⁴, E. Stites¹⁵, M. Mai¹⁶, M. Cooper¹⁷, D. Brennan¹⁸
¹Surgery, UW, Madison, WI, ²Surgery, Loyola, Chicago, IL, ³Surgery, Mayo, Rochester, MN, ⁴Surgery, Inova, Fairfax, VA, ⁵Surgery, Houston Methodist, Houston, TX, ⁶Nephrology, Yale, New Haven, CT, ⁷Surgery, Stanford, San Francisco, CA, ⁸Surgery, Intermountain, Murray, UT, ⁹Surgery, Loma Linda, Loma Linda, CA, ¹⁰Surgery, TJU, Philadelphia, PA, ¹¹Nephrology, St. Barnabas, Livingston, NJ, ¹²Surgery, UHH, Cincinnati, OH, ¹³Surgery, Upstate, Syracuse, NY, ¹⁴Surgery, CIUSSS, Montreal, ON, Canada, ¹⁵Nephrology, UC Denver, Denver, CO, ¹⁶Nephrology, Mayo - FL, Jacksonville, FL, ¹⁷Surgery, Georgetown, Washington, DC, ¹⁸Medeor, San Francisco, CA
*Purpose: We report interim results of the Phase 3 MERCURY tolerance study, which produces mixed chimerism and ultimately generates operational tolerance allowing for the elimination…
2021 American Transplant Congress
Late Subclinical Rejection and Borderline Rejection in Kidney Transplant Patients is Associated with Increased Incidence of Subsequent Clinical Rejections
V. Viswanathan¹, I. Melgarejo², C. Puttarajappa², P. Sood², M. Molinari², S. Hariharan², C. Wu², A. Sharma², N. Shah², R. Mehta²
¹Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The outcomes of inflammatory changes noted in late surveillance biopsies (1 year) is unclear.*Methods: Patients transplanted (live donor and deceased donor) at our center…
2021 American Transplant Congress
Limited Immunogenicity of a Single Dose of Sars-cov-2 Mrna Vaccine in Solid Organ Transplant Recipients
B. Boyarsky, M. Ou, R. Greenberg, A. Teles, W. Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik Wang
Johns Hopkins, Baltimore, MD
*Purpose: Given substantial challenges with vaccine allocation and evidence for short-term vaccine efficacy after a single dose of SARS-CoV-2 mRNA vaccines in clinical trials, some…